Levee Medical has announced the launch of a $10m Series B financing round to accelerate the development of its Voro Urologic Scaffold, a bioresorbable implant aimed at improving recovery outcomes after prostatectomy.

The capital will support regulatory and clinical activities, including broader clinical studies to validate the device's safety and efficacy.

The Voro Urologic Scaffold is designed to manage bladder neck geometry and maintain urethral length during prostatectomy, which is key to preventing post-operative incontinence.

Levee Medical has also launched the ALTO observational study in the US to evaluate urinary function and quality of life post-prostatectomy.

The Urology Place in San Antonio founder Dr Naveen Kella enrolled the first patient, as part of the ALTO study.

Kella said: “We are truly excited about the progress Levee Medical is making with the Voro Urologic Scaffold.

“Their clinically robust approach to developing this innovative solution is a testament to their commitment to improving patient outcomes. The preliminary results are encouraging, and I am confident their efforts will lead to significant advancements in the treatment of post-prostatectomy urinary incontinence.”

The company has made significant strides in its ARID feasibility study, evaluating the Voro Urologic Scaffold's safety and performance.

With 25 patients enrolled and five surgeons participating, the preliminary results are promising.

The Voro Urologic Scaffold, an absorbable device, aims to reduce the incidence of stress urinary incontinence significantly, offering a potential solution for patients undergoing radical prostatectomy.

In 2022, Levee Medical closed $6.6m in an initial oversubscribed series A financing round to fund the development of the Voro Urologic Scaffold.